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Abstract
Background: Circulating 25 hydroxyvitamin D (25 (OH)D), an accurate measure of vitamin D
status, is markedly greater in individuals with increased exposure to ultraviolet B (UVB) light via
sunlight or the use of artificial UV light. Aside from the known relationship between vitamin D and
bone, vitamin D has also been implicated in immune function and inflammation. Furthermore, a
mass of evidence is accumulating that vitamin D deficiency could lead to immune malfunction. Our
overall objective was to study the relationship between vitamin D status (as determined by serum
25(OH) D concentrations) and inflammatory markers in healthy women.
Methods: This observational study included 69 healthy women, age 25–82 years. Women with
high UVB exposure and women with minimal UVB exposure were specifically recruited to obtain
a wide-range of serum 25(OH)D concentrations. Health, sun exposure and habitual dietary intake
information were obtained from all subjects. Body composition was determined by dual-energy-x-
ray absorptiometry. A fasting blood sample was collected in the morning and analyzed for serum
25(OH)D, parathyroid hormone (iPTH), estradiol (E2), cortisol, and inflammatory markers [tumor
necrosis factor -alpha (TNF-α), interleukin-6 and -10 (IL-6, IL-10), and C-reactive protein (CRP)].
Results: Women with regular UVB exposure (Hi-D) had serum 25(OH)D concentrations that
were significantly higher (p < 0.0001) and iPTH concentrations that were significantly lower (p <
0.0001) than women without regular UVB exposure (Lo-D). Although IL-6, IL-10, and CRP did not
have a statistically significant relationship with 25(OH)D concentrations, linear regression models
revealed a significant inverse relationship between serum 25(OH)D and TNF-α concentrations.
This relationship remained significant after controlling for potential covariates such as body fat
mass, menopausal status, age, or hormonal contraceptive use.
Conclusion: Serum 25(OH)D status is inversely related to TNF-α concentrations in healthy
women, which may in part explain this vitamin's role in the prevention and treatment of
inflammatory diseases. Results gleaned from this investigation also support the need to re-examine
the biological basis for determining optimal vitamin D status.
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Background
Circulating 25 hydroxyvitamin D (25(OH)D), an accurate
measure of vitamin D status, is markedly increased in
individuals who receive regular exposure to ultraviolet B
(UVB) light via sunlight or the use of artificial UV light
(such as tanning beds) [1-6]. Serum 25(OH)D is hydrox-
ylated in the kidney, as well as in numerous other tissues,
to its active form, 1,25-dihydroxyvitamin D
(1,25(OH)2D). 1,25(OH)2D binds to nuclear vitamin D
receptors in tissues throughout the body. Active vitamin D
is responsible for maintaining calcium homeostasis pri-
marily by increasing the efficiency of intestinal calcium
absorption and by stimulating the differentiation of bone-
resorbing osteoclasts. Furthermore, vitamin D deficiency
increases secretion of parathyroid hormone, which accel-
erates bone breakdown and can lead to decreased bone
formation and density [7,8].
There is a growing body of data supporting the contention
that desirable serum 25(OH)D concentrations in healthy
individuals need to be set higher than the current values
to attain the optimal health benefits of vitamin D [8-11],
especially the benefits beyond calcium homeostasis [12-
14]. For no system does this ring truer than for the influ-
ence of vitamin D status on the immune system.
In the last few years, there has been an effort to under-
stand the possible noncalcemic (i.e. non-calcium regula-
tory) roles of vitamin D, including its role in the immune
system [15,16]. Most of the known biological effects of
1,25(OH)2D are mediated through the vitamin D receptor
(VDR); and, within the immune system, the VDR is found
in significant concentrations in the T lymphocyte and
macrophage populations [16]. Moreover, the enzyme
responsible for the final and rate-limiting hydroxylation
step in the synthesis of active vitamin D, 25(OH)D-1-a-
hydroxylase, is expressed by activated macrophages,
allowing these phagocytic cells to synthesize and secrete
1,25(OH)2D in a regulated fashion [17]. Additionally, the
major 1,25(OH)2D degrading enzyme, 24-hydroxylase, is
also expressed in monocytes/macrophages [18]. All of
these findings, then, suggest a paracrine role for vitamin D
in the immune system [19].
Evidence is accumulating that vitamin D deficiency may
lead to immune dysregulation. The relationship between
low serum 25(OH)D concentrations and autoimmune
disease (especially multiple sclerosis, Type I diabetes and
rheumatoid arthritis) has been appreciated for some time
[5,20,21]. More recently, studies have shown defective
macrophage function, such as impaired chemotaxis,
phagocytosis, and increased production of proinflamma-
tory cytokines, in vitamin D-insufficiency [18]. Vitamin D
has also been shown to downregulate the expression of
monocyte toll-like receptors (TLRs), known inducers of
inflammation that can prompt autoimmune disease exac-
erbation or sepsis [22]. In 2006, a double-blind, rand-
omized, placebo-controlled trial showed that vitamin D
supplementation improved cytokine profiles in patients
with congestive heart failure [12].
Several provocative reports have been published that also
support a role for vitamin D in reducing the risk of certain
infectious diseases [23,24], in part through the induction
of calthelcidin (also known as hCAP18, LL-37 and FALL-
39), an antimicrobial polypeptide [25]. For example, in
two seminal papers, Liu et al demonstrated that poor vita-
min D status may increase susceptibility to Mycobacterium
tuberculosis infection by inefficiently supporting the induc-
tion of cathelcidin mRNA in monocytes [26,27].
On balance, the published literature supports the need for
further inquiry into vitamin D status and its immune sys-
tem implications. Thus, our overall objective was to study
the relationship between vitamin D status (as determined
by serum 25(OH) D concentrations) and inflammatory
markers in healthy women. Women with high UVB expo-
sure and women with minimal UVB exposure were specif-
ically recruited to obtain a wide-range of serum 25(OH)D
concentrations [1,6,28] We hypothesized that serum
25(OH)D concentrations would be inversely correlated
with circulating concentrations of inflammatory markers.
Methods
Subject volunteers
This study used an observational, cross-sectional design to
explore the relationship between serum 25(OH)D con-
centrations and inflammatory marker concentrations in
healthy women. Ethical approval for this study was
received by the University of Missouri Health Sciences
Institutional Review Board (Project number 1069397).
Volunteers were recruited from the University of Missouri-
Columbia campus and surrounding community via email
notices and flyers posted on campus bulletin boards, and
at local tanning salons, fitness and community centers. To
be included in the study, volunteers had to be Caucasian
females who were at least 25 years of age. High vitamin D
women (Hi-D) had to have used a broad-spectrum tan-
ning bed at least once per week for a minimum of four
months. Low vitamin D women (Lo-D) had minimal
daily sunlight exposure, as assessed by a screening ques-
tionnaire, and did not use tanning beds. Volunteers were
excluded from the study if they: took a vitamin D supple-
ment other than a regular multivitamin; had a current or
previous medical condition or took a medication affecting
vitamin D status; had a current or previous medical con-
dition or took a medication affecting immune function;
had implanted metal that would interfere with the dual
energy x-ray absorptiometry (DXA) scan; were undergoingJournal of Inflammation 2008, 5:10 http://www.journal-inflammation.com/content/5/1/10
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ultraviolet radiation as medical therapy; exclusively used
high-pressure (UVA-only) tanning beds; exercised more
than 7 hours per week; were pregnant; or smoked ciga-
rettes.
Following an initial screening for inclusion and exclusion
criteria and after obtaining informed written consent,
qualified volunteers were scheduled for testing. Subjects
were instructed to refrain from exercise and to fast (water
only) for 8 to 10 hours prior to their scheduled morning
visit. On testing day, all subjects of childbearing age took
a urine pregnancy test to confirm non-pregnant status. All
study visits were conducted between late January and
early June of 2007, the predicted seasonal nadir of solar
UVB-produced serum 25(OH)D concentrations in mid-
Missourians [29].
Questionnaires and body composition
Four questionnaires were administered to all subjects: a
one-page health history and medical questionnaire devel-
oped for this study to collect data on previous health con-
ditions or diseases, menopausal status, current or
previous medication use, and exercise habits; a one-page
sun exposure questionnaire developed for this study to
assess tanning bed use, outdoor sun exposure, and sun-
screen use; a Fitzpatrick skin typing questionnaire, a well-
established method of determining skin pigmentation
and response to UVB exposure and thus potential for the
photosynthesis of vitamin D in the skin [30]; and, the 88-
question, self-administered Harvard Semi-quantitative
Food Frequency Questionnaire, a validated tool to assess
habitual dietary intake [31].
Body mass was measured without shoes to the nearest 0.1
kg and height to the nearest 0.5 cm using a medical bal-
ance beam scale. Body fat and lean body mass were meas-
ured by dual energy x-ray absorptiometry (DXA, Hologic
Delphi A bone densitometer, Bedford, MA).
Blood collection
All blood was drawn between the hours of 7:30 am and
11:30 am. Venous blood was collected into vacutainer
tubes and allowed to clot at room temperature for 30 min-
utes. The coagulated blood was centrifuged; the serum
was aliquoted into sterile microcentrifuge tubes, and
stored at -80°C.
Measurement of serum 25(OH)D
25(OH)D serum concentrations were measured using a
125I radioimmunoassay (RIA) kit (Diasorin, Stillwater,
MN, Intra-assay CV = 10.8%). The 25(OH)D RIA is a two-
step procedure. First, 25(OH)D and other hydroxylated
metabolites are rapidly extracted from serum using ace-
tonitrile. The extracted sample is then assayed using an
antibody with specificity to 25(OH)D.
Measurement of parathyroid hormone, estradiol and 
cortisol
Serum intact-PTH (iPTH) was measured using a commer-
cially-available iPTH (1–84) enzyme-linked immuno-
sorbent assay (ELISA) (ALPCO Diagnositics, Salem, NH,
Intra-assay CV = 2.5%). Serum estradiol and cortisol were
also measured using commercially available ELISA kits
(ALPCO Diagnostics, Salem, NH, Intra-assay CV = 7.7%
and 5.8%, respectively).
Measurement of inflammatory markers
Four inflammatory markers were measured: IL-10, C-reac-
tive protein (CRP), IL-6, and TNF-α. IL-10, IL-6, and TNF-
α, were measured using commercially available high sen-
sitivity ELISA kits (R&D Systems Inc., Minneapolis, MN,
Intra-assay CV = 5.3%, 7.4%, and 7.7%, respectively). An
ELISA was also used to measure CRP (R&D Systems Inc.,
Minneapolis, MN, Intra-assay CV = 5.5%).
Statistical analysis
Unpaired two-tailed t-tests were used to determine differ-
ences in subject characteristics and measured outcomes;
for data not normally distributed or of unequal variance,
a rank-sum test was performed. Linear regression and uni-
variate multiple regression models were used to deter-
mine the relationships between serum 25(OH)D and
serum inflammatory markers. All statistics were per-
formed using SAS statistical software version 9.1 (SAS Inc,
Cary, NC). Statistical significance was accepted when P <
0.05.
Results
Vitamin D status
Serum 25(OH)D concentrations of all subjects are pre-
sented in Figure 1. Sixty-nine women between the ages of
25 and 82 years participated in the study. Forty-nine of the
women were classified as Lo-D and 20 women were clas-
sified as Hi-D based on UVB exposure. The mean serum
25(OH)D status (nmol/L) of the Hi-D women (129.6 ±
11.0 nmol/L) was significantly higher than that of the Lo-
D women (74.4 ± 4.0 nmol/L) (P < 0.0001).
Subject characteristics and serum hormone concentrations
Subject characteristics and serum hormone concentra-
tions by vitamin D status are presented in Table 1. There
were no significant differences in age, height, weight, BMI,
percent body fat, hormonal contraceptive use or serum
estradiol or cortisol concentrations between vitamin D
status groups. The mean iPTH concentration of the Hi-D
women was significantly lower than that of the Lo-D
women (P < 0.0001). Furthermore, there was a significant
inverse relationship between 25(OH)D and iPTH concen-
trations (R2 = 0.2498; P = 0.0001). The skin type of the Hi-
D was significantly higher than that of the Lo-D group (P
= 0.0031). The Fitzpatrick skin typing method determinesJournal of Inflammation 2008, 5:10 http://www.journal-inflammation.com/content/5/1/10
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Table 1: Subject characteristics and serum hormone concentrations.
Characteristic/Hormone Lo-D (n = 49) Hi-D (n = 20) P Value
Age (years) 39.8 ± 1.8 41.7 ± 3.5 0.5733
Height (m) 1.70 ± 0.01 1.65 ± 0.01 0.6894
Weight (kg) 65.9 ± 1.6 67.9 ± 2.7 0.3800
Body Mass Index (kg/m2) 23.8 ± 0.5 25.0 ± 1.1 0.2488
Body Fat (%) 30.1 ± 1.0 30.6 ± 1.7 0.7665
Skin Type 2.4 ± 0.1 3.1 ± 0.2* 0.0031
Contraceptive Use (%) 31% 20% 0.3780
Estradiol (pg/mL) 158.0 ± 15.6 151.3 ± 15.3 0.7974
Cortisol (μg/dL) 8.4 ± 0.5 9.4 ± 1.2 0.3129
iPTH (pg/mL) 48.1 ± 3.1 26.2 ± 2.6* <0.0001
Subject characteristics and serum hormone concentrations of healthy women, age 25–82 years, categorized as low vitamin D status (Lo-D) or high 
vitamin D status (Hi-D) based on UVB exposure. Data are expressed as means ± SEM. *Significantly different from Lo-D, P < 0.05.
skin type based on pigmentation and ability to burn and/
or tan with sun exposure (Type I-IV, lighter-darker) [30].
Thus, it is not surprising that the Hi-D women had a
higher-level skin type because their skin is capable of tan-
ning; while women with lower-level skin types would not
be expected to use a tanning bed since their skin is less
able to tan. There were no differences between vitamin D
status groups for dietary intakes of energy, macronutrients
including omega-3 fatty acids, alcohol or caffeine (data
not shown).
Inflammatory marker outcomes
Mean serum TNF-α was significantly lower in the Hi-D
than the Lo-D women (1.22 ± 0.11 vs. 0.79 ± 0.11, P =
0.0200. IL-10, CRP and IL-6 did not significantly differ
between groups.
Figure 2 shows the relationships between 25 (OH)D and
IL-10, CRP, IL-6, and TNF-α. Serum 25(OH)D concentra-
tions were negatively correlated with TNF-α (R2 = 0.0605,
P = 0.0463). Thus, serum 25(OH)D status explained
6.05% of the variation in TNF-α concentrations. IL-10,
CRP and IL-6 concentrations were not significantly associ-
ated with the concentration of 25(OH)D in serum.
When controlling for percent body fat, menopausal sta-
tus, age, serum estradiol, serum cortisol, and hormonal
contraceptive use, a significant relationship (P < 0.05)
remained between 25(OH)D and TNF-α. Controlling for
percent body fat, menopausal status, age, serum estradiol,
serum cortisol, and hormonal contraceptive use did not
change the relationship between 25(OH)D concentra-
tions and IL-6, IL-10, and CRP. Analysis of potential cov-
ariates revealed a significant positive association between
age and IL-6 (R2 = 0.09413, P = 0.0116); and menopausal
status and IL-6 (R2 = 0.0764, P = 0.0246).
Discussion
The objective of the present study was to determine the
relationship between 25(OH)D concentrations and
inflammatory marker concentrations in healthy women.
Although IL-6, IL-10, and CRP did not have a statistically
significant relationship with 25(OH)D concentrations,
linear regression models revealed a significant inverse
relationship between serum 25(OH)D and serum TNF-α
concentrations. This relationship remained significant
after controlling for potential covariates such as body fat
mass, menopausal status, age, or hormonal contraceptive
use. Hinton et al. found that hormonal contraceptive use
was associated with greater TNF-α concentrations in
Serum 25(OH)D concentrations of Lo-D and Hi-D status  women Figure 1
Serum 25(OH)D concentrations of Lo-D and Hi-D 
status women. Mean (± SEM) serum 25(OH)D concentra-
tions of healthy women, age 25–82 years, categorized as low 
vitamin D status (Lo-D; n = 49) or high vitamin D status (Hi-
D; n = 20) based on UVB exposure. Single points for each 
category are means (± SEMS). *Significantly different from 
Lo-D, P < 0.0001.
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young female athletes [32]. Our data from healthy female
non-athletes representing a much wider age range did not
reveal such a relationship with TNF-α (P = 0.2336); how-
ever, like Hinton et al., there was a significant relationship
between hormonal contraceptive and serum cortisol level
(P = 0.0030). Interestingly, in our study serum 25(OH)D
remained a significant predictor of TNF-α even after con-
trolling for contraceptive use and cortisol concentrations.
The lack of significance between serum estradiol and any
of the inflammatory markers (data not shown) supports
previous research indicating that, in premenopausal
women, menstrual phase may affect circulating cytokine
concentrations, but the impact is generally not detectable
[33].
TNF-α is produced by numerous cell types, including
macrophages, monocytes, T-cells, smooth muscle cells,
adipocytes, and fibroblasts [34] many of which also have
VDR [14,15,35]. Thus, it is difficult to discern the specific
mechanisms by which elevations in systemic 25(OH)D
attenuate circulating TNF-α concentrations. Nonetheless,
our results agree with experimental data showing that
vitamin D is capable of suppressing TNF-α production
[36-39]. Zhu et al. recently showed that in the colonic tis-
sue of mice with inflammatory bowel disease,
1,25(OH)2D was capable of down-regulating several
genes associated with TNFα, including proteins involved
in the transcription of TNFα, one of its primary receptors,
and TNF-α itself [39].
Human studies of diseased populations have also shown
beneficial effects of vitamin D status on TNF-α concentra-
tions. Serum concentrations of TNF-α increased in unsup-
plemented congestive heart failure patients over a period
of 9 months, whereas serum TNF-α concentrations in
patients receiving daily supplementation of vitamin D
(2000 IU) remained constant [12]. Calcitriol
(1,25(OH)2D3) supplementation for 6 months in post-
menopausal women with osteoporosis resulted in a sig-
nificant reduction in serum TNF-α concentrations and an
The relationship between serum 25(OH)D concentrations and inflammatory marker concentrations Figure 2
The relationship between serum 25(OH)D concentrations and inflammatory marker concentrations. The rela-
tionship between serum 25(OH)D concentrations and serum IL-10, C-reactive protein (CRP), IL-6 and TNF-a concentrations 
in healthy women, ages 25–82 years (n = 69). Linear regression equations for each inflammatory marker are shown. * Slope of 
regression line significantly less than zero, P < 0.05.
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increase in bone mineral density [40]. Additionally, six
months of calcitriol supplementation in hemodialysis
patients also caused significant decreases in serum TNF-α
[41]. Our study is the first to show a significant inverse
relationship between serum 25(OH)D and TNF-α con-
centration in a healthy population.
TNF-α concentrations are increased in several disease
states such multiple sclerosis (MS), inflammatory bowel
disease (IBD), rheumatoid arthritis (RA), heart disease,
and osteoporosis; and are often correlated with clinical
impairment [42,43]. Therefore, attenuating the concen-
trations of circulating TNF-α has the potential to posi-
tively impact the risk for or treatment of such conditions.
Our data suggest that serum 25(OH)D status explains
~6% of the variation in TNF-α concentrations in healthy
women, thus a mild relationship.
Even a slight drop in circulating TNF-α due to improved
vitamin D status may have clinical significance. MS
patients with < 2 active brain lesions visible on magnetic
resonance imagery were shown to have serum TNF-α con-
centrations that were slightly but significantly (1.6 pg/
mL) less than those with ≥ 2 active brain lesions [44].
Patients with active ulcerative colitis were found to have
41% greater mean TNF-α concentrations than those with
inactive disease (9.46 and 5.54 pg/mL, respectively);
while, those with active Crohn's disease had TNF-α con-
centrations that were only 18% greater than patients with
inactive Crohn's (14.0 and 11.5 pg/mL, respectively) [45].
Increases in circulating TNF-α concentrations have been
associated with heart disease progression. Koller-Strametz
reported that TNF-α concentrations were 3.2 ± 0.2 pg/mL
in patients with New York Heart Association (NYHA)
function class II, 4.0 ± 0.3 pg/mL in NYHA function class
III patients, and 5.3 ± 0.9 pg/mL in NYHA function class
IV patients [46].
Anti-TNF-α medications are efficacious in the manage-
ment of IBD [47]. Martinez-Borra et al. found that patients
with lower TNF-α concentrations (14 ± 25 pg/mL) prior to
treatment with the anti-TNF drug, infliximab, responded
to the treatment, whereas non-responders had signifi-
cantly higher baseline serum concentrations (201 ± 362
pg/mL) [48]. Therefore, it is possible vitamin D supple-
mentation may be a viable adjunct to anti-TNF therapy.
Human studies involving diseased populations have
shown positive relationships between 25(OH)D concen-
trations and IL-10 [12]. Despite this evidence, in the
present study, serum IL-10 was not significantly correlated
with serum 25(OH)D, suggesting that in healthy adults,
vitamin D status does not affect IL-10 secretion into sys-
temic circulation.
Similarly, serum 25(OH)D and serum CRP were not cor-
related in the present study. As a non-specific inflamma-
tory marker of general wellness, CRP increases with mild
chronic infection, aging, and tissue damage [49]. Research
in diseased populations, such as diabetes [50], arthritis
[51,52], prolonged chronic illness [53], and clinical vita-
min D deficiency (25(OH)D <27.5 nmol/L) [54] have
demonstrated negative associations between vitamin D
status and CRP concentrations. Nevertheless, intervention
studies of healthy post-menopausal women [55] and
patients with congestive heart failure [12] failed to see
changes in CRP concentrations after vitamin D supple-
mentation.
Although the result of the linear regression analysis was
not statistically significant, there appears to be a slight ten-
dency towards an inverse relationship between 25(OH)D
concentrations and serum IL-6 (P = 0.0909). Several in
vitro studies have shown that 1,25(OH)2D and several of
its analogs are capable of inhibiting the production of IL-
6 in various cell types [38,56-59]; while most published in
vivo studies have failed to show an effect of vitamin D sta-
tus on circulating IL-6 concentrations in humans
[12,52,60,61]. One report, however, involving hemodial-
ysis patients with elevated parathyroid hormone (PTH)
demonstrated that both oral and intravenous
1,25(OH)2D supplementation were capable of signifi-
cantly decreasing serum IL-6 concentrations following 6
months of treatment [62]. It has been well documented
that PTH induces the production of IL-6 by osteoblasts
[63,64], thus, it is likely that the effects of vitamin D sup-
plementation on serum IL-6 in this population were
mediated primarily through the inverse relationship
between 25(OH)D and PTH. In our study, there was no
relationship between intact PTH and IL-6 concentrations
(P = 0.8039). The significant relationship found between
age and IL-6 (P = 0.0116) in this study was anticipated
due to several reports showing that circulating IL-6 con-
centrations increase with advancing age [65-68]. Further,
IL-6 has been implicated in age-associated diseases (such
as lymphoproliferative disorders, multiple myeloma,
osteoporosis, and Alzheimer's disease) and frailty; and, it
is postulated that certain clinically important late-life
changes are due to an inappropriate presence of IL-6.
Therefore, our results indicating a trend for a negative rela-
tionship between vitamin D status and IL-6 concentra-
tions warrants further investigation. The lowering of
circulating IL-6 through the improvement of vitamin D
nutriture may have the potential to decrease disability and
mortality in older populations in addition to helping
maintain muscle strength and bone health.
The range of serum 25 (OH)D concentrations observed in
our healthy female subjects are in accordance with the
overwhelming number of reports documenting the preva-Journal of Inflammation 2008, 5:10 http://www.journal-inflammation.com/content/5/1/10
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lence of vitamin D deficiency and insufficiency in the gen-
eral population [69-75]. In recent years, mounting data
has highlighted the need to re-examine vitamin D status
and recommendations [76]. Bischoff-Ferrari et al. summa-
rized results from randomized controlled trials, prospec-
tive and cross-sectional epidemiologic studies, strong
mechanistic evidence, and dose-response relationships to
determine an optimal serum 25(OH)D concentration
[77]. They showed that for all endpoints (bone mineral
density, lower-extremity function, dental health, and risk
of falls, fractures, and colorectal cancer), optimal
25(OH)D status began at 75 nmol/L. Our study demon-
strates that like these other health outcomes, circulating
TNF-α concentrations continue to be associated with
serum 25(OH)D concentrations above this point, in a
manner consistent with decreased disease risk/progres-
sion (i.e. lower TNF-α concentrations).
The primary limitation of this study was sample size.
Women who were regularly exposed to UVB light and
qualified to participate based on our inclusion and exclu-
sion criteria were far more difficult to recruit than women
with minimal UVB exposure. Additionally, women who
tan regularly are inherently different from non-tanners.
Frequent tanning bed use is associated with high risk
behaviours, including frequent dieting, laxative use or
vomiting to control weight, cigarette smoking, binge
drinking, and recreational drug use. [78]. In light of this,
the present study was designed to control or account for
these behaviors through subject inclusion/exclusion crite-
ria and inclusion of pertinent questionnaire data in the
multiple regression analysis.
Conclusion
Serum TNF-α concentrations are negatively correlated
with vitamin D status in healthy women. This study is the
first known report to show this inverse relationship in a
non-diseased population. Results gleaned from this inves-
tigation also support the need to re-examine the biologi-
cal basis for determining optimal vitamin D status. More
studies are needed to fully characterize the relationship
between vitamin D and TNF-α relationship; but if proven
effective, vitamin D therapy may show promise as adjunct
to anti-TNF therapy in inflammatory disease states.
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